{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:27:14Z","timestamp":1790015234738,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","award":["22S276"],"award-info":[{"award-number":["22S276"]}]},{"name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","award":["22S276"],"award-info":[{"award-number":["22S276"]}]},{"name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","award":["22S276"],"award-info":[{"award-number":["22S276"]}]},{"name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","award":["22S276"],"award-info":[{"award-number":["22S276"]}]},{"name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","award":["22S276"],"award-info":[{"award-number":["22S276"]}]},{"name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","award":["22S276"],"award-info":[{"award-number":["22S276"]}]},{"name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","award":["22S276"],"award-info":[{"award-number":["22S276"]}]},{"DOI":"10.13039\/501100016003","name":"Istanbul \u00dcniversitesi-Cerrahpasa","doi-asserted-by":"crossref","award":["TTU-2022-36413"],"award-info":[{"award-number":["TTU-2022-36413"]}],"id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016003","name":"Istanbul \u00dcniversitesi-Cerrahpasa","doi-asserted-by":"crossref","award":["TTU-2022-36413"],"award-info":[{"award-number":["TTU-2022-36413"]}],"id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016003","name":"Istanbul \u00dcniversitesi-Cerrahpasa","doi-asserted-by":"crossref","award":["TTU-2022-36413"],"award-info":[{"award-number":["TTU-2022-36413"]}],"id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016003","name":"Istanbul \u00dcniversitesi-Cerrahpasa","doi-asserted-by":"crossref","award":["TTU-2022-36413"],"award-info":[{"award-number":["TTU-2022-36413"]}],"id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016003","name":"Istanbul \u00dcniversitesi-Cerrahpasa","doi-asserted-by":"crossref","award":["TTU-2022-36413"],"award-info":[{"award-number":["TTU-2022-36413"]}],"id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016003","name":"Istanbul \u00dcniversitesi-Cerrahpasa","doi-asserted-by":"crossref","award":["TTU-2022-36413"],"award-info":[{"award-number":["TTU-2022-36413"]}],"id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016003","name":"Istanbul \u00dcniversitesi-Cerrahpasa","doi-asserted-by":"crossref","award":["TTU-2022-36413"],"award-info":[{"award-number":["TTU-2022-36413"]}],"id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to explore the potential value of urinary cell-free microRNA (miR)-93-5p, miR-191-5p, and miR-31-5p levels in the non-invasive prediction of basal-like and luminal-like invasive urothelial carcinoma immune signature phenotypes according to the molecular classification of bladder cancer, by comparing their expression in patients and healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included morning urine samples from 49 bladder cancer patients and 43 controls. A quantitative image-based immunohistochemical analysis classified tumor cases into basal-like and luminal-like subtypes. Quantitative real-time PCR (qRT-PCR) was used to measure cell-free miR-93-5p, miR-191-5p, and miR-31-5p expression levels in urine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MiR-191-5p was significantly downregulated in bladder cancer patients compared to healthy controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with a 24-fold decrease. Notably, miR-191-5p levels were markedly lower in the luminal-like subtype relative to the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In contrast, miR-93-5p was significantly upregulated in the basal-like subtype, showing a 4.15-fold increase compared to controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Elevated levels of miR-93-5p were also observed in high-grade tumors (3.4-fold,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), in tumors exhibiting necrosis (3.4-fold,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and in the presence of carcinoma in situ (CIS) (2.6-fold,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Furthermore, miR-93-5p levels showed a positive correlation with tumor size (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In this exploratory cohort, miR-93-5p also demonstrated strong discriminatory performance in identifying CK5\/6-positive tumors, with a receiver operating characteristic (ROC) curve cut-off value of 1.57 for 2^\n                      <jats:sup>\u0394\u0394<\/jats:sup>\n                      CT value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this single-center, exploratory study, urinary cell-free miR-93-5p and miR-191-5p showed potential utility as non-invasive biomarkers for rapid molecular subtype identification in bladder cancer. miR-93-5p was associated with basal-like (aggressive) tumor features, while miR-191-5p was inversely associated with invasive urothelial carcinoma. miR-31-5p appears to serve as a complementary marker, especially in cases of CIS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-026-02047-y","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:04:21Z","timestamp":1768446261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical utility of cell-free urine miR-93-5p, miR-191-5p, miR-31-5p for invasive urothelial carcinoma detection and immune signature-based subtyping"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3000-9749","authenticated-orcid":false,"given":"Sami Berk","family":"\u00d6zden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysel","family":"Kalayc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130clal","family":"G\u00fcrses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filiz","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130pek","family":"Sertbudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furkan","family":"Kuzucu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7etin","family":"Demirda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"2047_CR1","unstructured":"International Agency for Research on Cancer. World fact sheet (GLOBOCAN 2020). World Health Organization. 2020. Retrieved December 19, 2025, from https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"issue":"6","key":"2047_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.juro.2013.11.056","volume":"191","author":"ON Gofrit","year":"2014","unstructured":"Gofrit ON, Pizov G, Shapiro A, et al. Mixed high and low grade bladder Tumors\u2014Are they clinically high or low grade? J Urol. 2014;191(6):1693\u20136. https:\/\/doi.org\/10.1016\/j.juro.2013.11.056.","journal-title":"J Urol"},{"key":"2047_CR3","doi-asserted-by":"publisher","unstructured":"Paner GP, Kamat A, Netto GJ et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. 2024;48(1):e11-e23. https:\/\/doi.org\/10.1097\/PAS.0000000000002077.","DOI":"10.1097\/PAS.0000000000002077"},{"issue":"2","key":"2047_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of Muscle-Invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152\u201365. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.009.","journal-title":"Cancer Cell"},{"issue":"1","key":"2047_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/BLC-150037","volume":"2","author":"SP Lerner","year":"2016","unstructured":"Lerner SP, McConkey DJ, Hoadley KA, et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer. 2016;2(1):37\u201347. https:\/\/doi.org\/10.3233\/BLC-150037.","journal-title":"Bladder Cancer"},{"issue":"3","key":"2047_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of Muscle-Invasive bladder cancer. Cell. 2017;171(3):540\u2013e55625. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007.","journal-title":"Cell"},{"issue":"7","key":"2047_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","volume":"21","author":"CC Guo","year":"2024","unstructured":"Guo CC, Lee S, Lee JG, et al. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat Rev Urol. 2024;21(7):391\u2013405. https:\/\/doi.org\/10.1038\/s41585-023-00847-7.","journal-title":"Nat Rev Urol"},{"key":"2047_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania V, Zhang M, Zhang L, et al. Meta-Analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016;12:105\u201317. https:\/\/doi.org\/10.1016\/j.ebiom.2016.08.036.","journal-title":"EBioMedicine"},{"key":"2047_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/978-1-4419-9863-7_1118","volume-title":"Encyclopedia of systems biology","author":"K Nieselt","year":"2013","unstructured":"Nieselt K, Herbig A. Non-coding RNA, classification. In: Dubitzky W, Wolkenhauer O, Cho KH, Yokota H, editors. Encyclopedia of systems biology. New York: Springer; 2013. pp. 1532\u20134. https:\/\/doi.org\/10.1007\/978-1-4419-9863-7_1118."},{"key":"2047_CR10","doi-asserted-by":"publisher","unstructured":"Hombach S, Kretz M. Non-coding RNAs: Classification, Biology and Functioning. In: Slaby O, Calin GA, eds. Non-Coding RNAs in Colorectal Cancer. Vol 937. Advances in Experimental Medicine and Biology. Springer International Publishing; 2016:3\u201317. https:\/\/doi.org\/10.1007\/978-3-319-42059-2_1.","DOI":"10.1007\/978-3-319-42059-2_1"},{"issue":"Suppl 1","key":"2047_CR11","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.4111\/icu.2016.57.S1.S60","volume":"57","author":"H Enokida","year":"2016","unstructured":"Enokida H, Yoshino H, Matsushita R, Nakagawa M. The role of MicroRNAs in bladder cancer. Investig Clin Urol. 2016;57(Suppl 1):S60. https:\/\/doi.org\/10.4111\/icu.2016.57.S1.S60.","journal-title":"Investig Clin Urol"},{"issue":"1","key":"2047_CR12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1186\/s12885-021-08926-x","volume":"21","author":"H Lin","year":"2021","unstructured":"Lin H, Shi X, Li H, et al. Urinary Exosomal MiRNAs as biomarkers of bladder cancer and experimental verification of mechanism of miR-93-5p in bladder cancer. BMC Cancer. 2021;21(1):1293. https:\/\/doi.org\/10.1186\/s12885-021-08926-x.","journal-title":"BMC Cancer"},{"issue":"4","key":"2047_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/bjc.2015.472","volume":"114","author":"N Sapre","year":"2016","unstructured":"Sapre N, Macintyre G, Clarkson M, et al. A urinary MicroRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. Br J Cancer. 2016;114(4):454\u201362. https:\/\/doi.org\/10.1038\/bjc.2015.472.","journal-title":"Br J Cancer"},{"issue":"3","key":"2047_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5301\/jbm.5000199","volume":"31","author":"S Xiao","year":"2016","unstructured":"Xiao S, Wang J, Xiao N. MicroRNAs as noninvasive biomarkers in bladder cancer detection: A diagnostic Meta-Analysis based on qRT-PCR data. Int J Biol Markers. 2016;31(3):276\u201385. https:\/\/doi.org\/10.5301\/jbm.5000199.","journal-title":"Int J Biol Markers"},{"issue":"10","key":"2047_CR15","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/ijc.29895","volume":"138","author":"G Matullo","year":"2016","unstructured":"Matullo G, Naccarati A, Pardini B. Micro RNA expression profiling in bladder cancer: the challenge of next-generation sequencing in tissues and biofluids. Intl J Cancer. 2016;138(10):2334\u201345. https:\/\/doi.org\/10.1002\/ijc.29895.","journal-title":"Intl J Cancer"},{"issue":"1","key":"2047_CR16","doi-asserted-by":"publisher","first-page":"41e","DOI":"10.1016\/j.urolonc.2013.04.011","volume":"32","author":"H Mlcochova","year":"2014","unstructured":"Mlcochova H, Hezova R, Stanik M, Slaby O. Urine MicroRNAs as potential noninvasive biomarkers in urologic cancers. Urologic Oncology: Seminars Original Investigations. 2014;32(1):41e. 1-41.e9.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"2047_CR17","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3389\/fonc.2019.01266","volume":"9","author":"U Satyal","year":"2019","unstructured":"Satyal U, Srivastava A, Abbosh PH. Urine Biopsy\u2014Liquid gold for molecular detection and surveillance of bladder cancer. Front Oncol. 2019;9:1266. https:\/\/doi.org\/10.3389\/fonc.2019.01266.","journal-title":"Front Oncol"},{"issue":"2","key":"2047_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3892\/ijo.2014.2752","volume":"46","author":"T Chiyomaru","year":"2015","unstructured":"Chiyomaru T, Seki N, Inoguchi S, et al. Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b\/27b cluster in bladder cancer. Int J Oncol. 2015;46(2):487\u201396. https:\/\/doi.org\/10.3892\/ijo.2014.2752.","journal-title":"Int J Oncol"},{"key":"2047_CR19","doi-asserted-by":"publisher","unstructured":"Majid S, Dar AA, Saini S et al. MicroRNA-23b Functions as a Tumor Suppressor by Regulating Zeb1 in Bladder Cancer. Chai KX, ed. PLoS ONE. 2013;8(7):e67686. https:\/\/doi.org\/10.1371\/journal.pone.0067686.","DOI":"10.1371\/journal.pone.0067686"},{"issue":"7","key":"2047_CR20","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1158\/1078-0432.CCR-13-2805","volume":"20","author":"RM Drayton","year":"2014","unstructured":"Drayton RM, Dudziec E, Peter S, et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the Cystine\/Glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20(7):1990\u20132000. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2805.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2047_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.eururo.2022.08.011","volume":"82","author":"C Suarez-Cabrera","year":"2022","unstructured":"Suarez-Cabrera C, Estudillo L, Ram\u00f3n-Gil E, et al. BlaDimiR: A Urine-based MiRNA score for accurate bladder cancer diagnosis and Follow-up. Eur Urol. 2022;82(6):663\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.011.","journal-title":"Eur Urol"},{"issue":"3","key":"2047_CR22","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1111\/jcmm.13487","volume":"22","author":"J Juracek","year":"2018","unstructured":"Juracek J, Peltanova B, Dolezel J, et al. Genome-wide identification of urinary cell\u2010free micro RNA s for non\u2010invasive detection of bladder cancer. J Cell Mol Medi. 2018;22(3):2033\u20138. https:\/\/doi.org\/10.1111\/jcmm.13487.","journal-title":"J Cell Mol Medi"},{"issue":"1","key":"2047_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13046-024-02966-4","volume":"43","author":"T Li","year":"2024","unstructured":"Li T, Huang M, Sun N, et al. Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation. J Exp Clin Cancer Res. 2024;43(1):50. https:\/\/doi.org\/10.1186\/s13046-024-02966-4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"2047_CR24","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1261\/rna.060657.117","volume":"23","author":"S Sharma","year":"2017","unstructured":"Sharma S, Nagpal N, Ghosh PC, Kulshreshtha R. P53-miR-191- SOX4 regulatory loop affects apoptosis in breast cancer. RNA. 2017;23(8):1237\u201346. https:\/\/doi.org\/10.1261\/rna.060657.117.","journal-title":"RNA"},{"issue":"14","key":"2047_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1080\/15384101.2022.2054095","volume":"21","author":"Y Chen","year":"2022","unstructured":"Chen Y, Ji S, Ying J, Sun Y, Liu J, Yin G. KRT6A expedites bladder cancer progression, regulated by miR-31-5p. Cell Cycle. 2022;21(14):1479\u201390. https:\/\/doi.org\/10.1080\/15384101.2022.2054095.","journal-title":"Cell Cycle"},{"issue":"19","key":"2047_CR26","doi-asserted-by":"publisher","first-page":"32370","DOI":"10.18632\/oncotarget.16026","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Liu X, Wu Y, et al. MicroRNAs in biofluids are novel tools for bladder cancer screening. Oncotarget. 2017;8(19):32370\u20139. https:\/\/doi.org\/10.18632\/oncotarget.16026.","journal-title":"Oncotarget"},{"issue":"3","key":"2047_CR27","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.18632\/oncotarget.6487","volume":"7","author":"X Zhang","year":"2016","unstructured":"Zhang X, Zhang Y, Liu X, et al. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer. Oncotarget. 2016;7(3):3255\u201366. https:\/\/doi.org\/10.18632\/oncotarget.6487.","journal-title":"Oncotarget"},{"issue":"8","key":"2047_CR28","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/jso.23937","volume":"111","author":"J Wang","year":"2015","unstructured":"Wang J, Zhang X, Wang L, et al. Downregulation of urinary cell-free microRNA\u2010214 as a diagnostic and prognostic biomarker in bladder cancer. J Surg Oncol. 2015;111(8):992\u20139. https:\/\/doi.org\/10.1002\/jso.23937.","journal-title":"J Surg Oncol"},{"key":"2047_CR29","doi-asserted-by":"publisher","unstructured":"Zhang DZ, Lau KM, Chan ESY et al. Cell-Free Urinary MicroRNA-99a and MicroRNA-125b Are Diagnostic Markers for the Non-Invasive Screening of Bladder Cancer. Dahiya R, ed. PLoS ONE. 2014;9(7):e100793. https:\/\/doi.org\/10.1371\/journal.pone.0100793.","DOI":"10.1371\/journal.pone.0100793"},{"issue":"7","key":"2047_CR30","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2007.04.040","volume":"129","author":"P Landgraf","year":"2007","unstructured":"Landgraf P, Rusu M, Sheridan R, et al. A mammalian MicroRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401\u201314. https:\/\/doi.org\/10.1016\/j.cell.2007.04.040.","journal-title":"Cell"},{"issue":"3","key":"2047_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2008.02.013","volume":"13","author":"F Petrocca","year":"2008","unstructured":"Petrocca F, Visone R, Onelli MR, et al. E2F1-Regulated MicroRNAs impair TGF\u03b2-Dependent Cell-Cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13(3):272\u201386. https:\/\/doi.org\/10.1016\/j.ccr.2008.02.013.","journal-title":"Cancer Cell"},{"issue":"4","key":"2047_CR32","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3892\/or.2017.5859","volume":"38","author":"S Chu","year":"2017","unstructured":"Chu S, Liu G, Xia P, et al. miR-93 and PTEN: key regulators of doxorubicin-resistance and EMT in breast cancer. Oncol Rep. 2017;38(4):2401\u20137. https:\/\/doi.org\/10.3892\/or.2017.5859.","journal-title":"Oncol Rep"},{"issue":"2","key":"2047_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.urolonc.2018.08.001","volume":"37","author":"H Jiang","year":"2019","unstructured":"Jiang H, Bu Q, Zeng M, Xia D, Wu A. MicroRNA-93 promotes bladder cancer proliferation and invasion by targeting PEDF. Urologic Oncology: Seminars Original Investigations. 2019;37(2):150\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2018.08.001.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"issue":"4","key":"2047_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.21037\/atm-22-97","volume":"10","author":"M Yang","year":"2022","unstructured":"Yang M, Xiao R, Wang X, Xiong Y, Duan Z, Li D, Kan Q. MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1\/CCND1 in breast cancer. Ann Transl Med. 2022;10(4):203. https:\/\/doi.org\/10.21037\/atm-22-97. PMID: 35280383; PMCID: PMC8908185.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2047_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.yexcr.2017.05.007","volume":"357","author":"Y Xiang","year":"2017","unstructured":"Xiang Y, Liao XH, Yu CX, et al. MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3. Exp Cell Res. 2017;357(1):135\u201344. https:\/\/doi.org\/10.1016\/j.yexcr.2017.05.007.","journal-title":"Exp Cell Res"},{"key":"2047_CR36","doi-asserted-by":"publisher","first-page":"897751","DOI":"10.3389\/fonc.2022.897751","volume":"12","author":"X Su","year":"2022","unstructured":"Su X, Xue C, Xie C, et al. lncRNA-LET regulates Glycolysis and glutamine decomposition of esophageal squamous cell carcinoma through miR-93-5p\/miR-106b-5p\/SOCS4. Front Oncol. 2022;12:897751. https:\/\/doi.org\/10.3389\/fonc.2022.897751.","journal-title":"Front Oncol"},{"issue":"2","key":"2047_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.21037\/tau-22-872","volume":"12","author":"F Yuan","year":"2023","unstructured":"Yuan F, Yin XY, Huang Y, et al. Exosomal miR-93-5p as an important driver of bladder cancer progression. Transl Androl Urol. 2023;12(2):286\u201399. https:\/\/doi.org\/10.21037\/tau-22-872.","journal-title":"Transl Androl Urol"},{"issue":"2","key":"2047_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/ijc.31849","volume":"144","author":"X Piao","year":"2019","unstructured":"Piao X, Jeong P, Kim Y, et al. Urinary cell-free MicroRNA biomarker could discriminate bladder cancer from benign hematuria. Intl J Cancer. 2019;144(2):380\u20138. https:\/\/doi.org\/10.1002\/ijc.31849.","journal-title":"Intl J Cancer"},{"issue":"8","key":"2047_CR39","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1096\/fj.201601263R","volume":"31","author":"Y Gu","year":"2017","unstructured":"Gu Y, Ampofo E, Menger MD, Laschke MW. miR-191 suppresses angiogenesis by activation of NF\u2010kB signaling. FASEB J. 2017;31(8):3321\u201333. https:\/\/doi.org\/10.1096\/fj.201601263R.","journal-title":"FASEB J"},{"key":"2047_CR40","doi-asserted-by":"publisher","unstructured":"Polioudakis D, Abell NS, Iyer VR. MiR-191 Regulates Primary Human Fibroblast Proliferation and Directly Targets Multiple Oncogenes. Navarro A, ed. PLoS ONE. 2015;10(5):e0126535. https:\/\/doi.org\/10.1371\/journal.pone.0126535.","DOI":"10.1371\/journal.pone.0126535"},{"issue":"2","key":"2047_CR41","first-page":"444","volume":"23","author":"X Wang","year":"2018","unstructured":"Wang X, Shi Z, Liu X, et al. Upregulation of miR-191 promotes cell growth and invasion via targeting TIMP3 in prostate cancer. J BUON. 2018;23(2):444\u201352.","journal-title":"J BUON"},{"issue":"12","key":"2047_CR42","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/carcin\/bgy102","volume":"39","author":"X Zhang","year":"2018","unstructured":"Zhang X, Wu M, Chong QY, et al. Amplification of hsa-miR-191\/425 locus promotes breast cancer proliferation and metastasis by targeting DICER1. Carcinogenesis. 2018;39(12):1506\u201316. https:\/\/doi.org\/10.1093\/carcin\/bgy102.","journal-title":"Carcinogenesis"},{"key":"2047_CR43","doi-asserted-by":"publisher","first-page":"118330","DOI":"10.1016\/j.biopha.2025.118330","volume":"189","author":"F Porcel-Pastrana","year":"2025","unstructured":"Porcel-Pastrana F, Montero-Hidalgo AJ, Herrero-Aguayo V, et al. miR-191\u20135p: A tumour suppressor MiRNA and a personalized biomarker and potential therapeutic tool connecting prostate cancer and obesity. Biomed Pharmacother. 2025;189:118330. https:\/\/doi.org\/10.1016\/j.biopha.2025.118330.","journal-title":"Biomed Pharmacother"},{"issue":"46","key":"2047_CR44","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3760\/cma.j.cn112137-20200407-01111","volume":"100","author":"NJ Cao","year":"2020","unstructured":"Cao NJ, Hou HH, Li F, Guo ST, Wang Y. Zhonghua Yi Xue Za Zhi. 2020;100(46):3689\u201393. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20200407-01111.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"2047_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40164-025-00649-0","volume":"14","author":"J Oto","year":"2025","unstructured":"Oto J, Herranz R, Plana E, et al. Validation of a MicroRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan. Exp Hematol Oncol. 2025;14(1):58. https:\/\/doi.org\/10.1186\/s40164-025-00649-0.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"2047_CR46","first-page":"1439","volume":"12","author":"HY Wu","year":"2019","unstructured":"Wu HY, Li MW, Li QQ, et al. Elevation of miR-191-5p level and its potential signaling pathways in hepatocellular carcinoma: a study validated by microarray and in-house qRT-PCR with 1,291 clinical samples. Int J Clin Exp Pathol. 2019;12(4):1439\u201356. Published 2019 Apr 1.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2047_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41420-022-00948-z","volume":"8","author":"X Lin","year":"2022","unstructured":"Lin X, Wu W, Ying Y, et al. MicroRNA-31: a pivotal oncogenic factor in oral squamous cell carcinoma. Cell Death Discov. 2022;8(1):140. https:\/\/doi.org\/10.1038\/s41420-022-00948-z.","journal-title":"Cell Death Discov"},{"issue":"5","key":"2047_CR48","doi-asserted-by":"publisher","first-page":"e1694","DOI":"10.1002\/ctm2.1694","volume":"14","author":"P Zhang","year":"2024","unstructured":"Zhang P, Guan L, Sun W, et al. Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAFV600E \u2010associated thyroid carcinoma. Clin Translational Med. 2024;14(5):e1694. https:\/\/doi.org\/10.1002\/ctm2.1694.","journal-title":"Clin Translational Med"},{"issue":"5","key":"2047_CR49","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00404-015-3713-2","volume":"292","author":"W Zheng","year":"2015","unstructured":"Zheng W, Liu Z, Zhang W, Hu X. miR-31 functions as an oncogene in cervical cancer. Arch Gynecol Obstet. 2015;292(5):1083\u20139. https:\/\/doi.org\/10.1007\/s00404-015-3713-2.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"2047_CR50","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1038\/s41598-018-27521-y","volume":"8","author":"\u00c1 Nagy","year":"2018","unstructured":"Nagy \u00c1, L\u00e1nczky A, Menyh\u00e1rt O, Gy\u0151rffy B. Validation of MiRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. https:\/\/doi.org\/10.1038\/s41598-018-27521-y.","journal-title":"Sci Rep"},{"issue":"1","key":"2047_CR51","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s11033-024-10010-z","volume":"51","author":"E Erturk","year":"2024","unstructured":"Erturk E, Ari F, Onur OE, Gokgoz SM, Tolunay S. Correction: Value of miR-31 and mir-150-3p as diagnostic and prognostic biomarkers for breast cancer. Mol Biol Rep. 2024;51(1):1086. https:\/\/doi.org\/10.1007\/s11033-024-10010-z.","journal-title":"Mol Biol Rep"},{"key":"2047_CR52","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.biopha.2018.10.048","volume":"109","author":"H Peng","year":"2019","unstructured":"Peng H, Wang L, Su Q, Yi K, Du J, Wang Z. MiR-31-5p promotes the cell growth, migration and invasion of colorectal cancer cells by targeting NUMB. Biomed Pharmacother. 2019;109:208\u201316. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.048.","journal-title":"Biomed Pharmacother"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02047-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02047-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02047-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:45:43Z","timestamp":1781628343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02047-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2047"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02047-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Istanbul University- Clinical Research Ethics Committee (Approval No: E-29624016-050.99-749992). All participants provided written informed consent prior to enrollment. The study was conducted in accordance with the ethical standards outlined in the Declaration of Helsinki and its subsequent amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}